Compare Honeywell International Inc (HON) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Sana Biotechnology Inc — how do they compare? Honeywell International Inc trades at $207.77 (market cap $65.48B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Honeywell International Inc is far larger — about 78.3× Sana Biotechnology Inc's market cap, and Honeywell International Inc pays a 1.36% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 91 Days and Sana Biotechnology Inc for 23 Days on average.
| HON | SANA | |
|---|---|---|
Market Cap | $65.48B | $836.71M |
Volume | 2,047,782 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $248.79 | $5.92 |
52-Week Low | $188.14 | $2.68 |
Typical Hold Time | 91 Days | 23 Days |
Enterprise Value | $90.27B | $749.96M |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.12 with minimal daily movement, showing strong profitability metrics including 21.6% net margin and 47.4% ROE. The company recently completed a strategic split into three focused businesses and secured a $300 million refinery project, positioning for growth in automation. Technical indicators show bearish momentum with support at $205 and resistance at $208, while fundamentals reveal attractive valuation with P/E of 7.9x below industry averages.
HON presents a compelling value opportunity with analyst consensus target of $259.25 representing 25% upside potential. The company's post-spin growth story is gaining momentum with recent earnings beats, though investors should monitor debt levels that have increased to 47.7% of assets and potential execution risks from the corporate restructuring.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
